Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May;58(3):181-7.
doi: 10.4103/0019-5154.110824.

Immunohistochemical evaluation of p53 and Ki67 expression in skin epithelial tumors

Effat Khodaeiani  1 , Ashraf Fakhrjou, Mehdi Amirnia, Shahla Babaei-Nezhad, Farshid Taghvamanesh, Elham Razzagh-Karimi, Hossein Alikhah
Affiliations

Immunohistochemical evaluation of p53 and Ki67 expression in skin epithelial tumors

Effat Khodaeiani et al. Indian J Dermatol. 2013 May.

Abstract

Background and aims: The cellular mechanisms responsible for initiating or limiting the tumors including skin types are of great importance. The p53 is a tumor-inhibiting gene which is believed to be defective in many malignant situations. Ki67 is a non-histonic protein which is mainly interfere with the proliferation and has many controlling effects during the cell cycle. Because of their importance in skin tumor cell growth, this study aimed at evaluating the p53 and Ki67 expression in skin epithelial tumors by immunohistochemical method.

Materials and methods: In a descriptive setting, 50 biopsy samples (30 basal cell carcinomas (BCCs), 10 squamous cell carcinomas (SCCs), 8 keratoacanthomas (KAs), and 2 trichoepitheliomas (TEs)) were immunohistochemically evaluated for p53 and Ki67 expression during a 14-month period. The incidence and expression rate of these two variables were separately reported in each group of samples.

Results: The expression rate of p53 was 67.77% for the BCCs, 50.20% for the SCCs, and null for the KAs. For both TEs, it was 50%. The expression rate of Ki67 was 57.33% for the BCCs, 47.70% for the SCCs, 37.5% for the KAs, and 0.0% for TEs. The incidence of P53+ cells was 100% and 90% in the BCC and SCC samples, respectively. The both TEs were positive in this regard. The incidence of Ki67+ cells was 100% for the BCC, SCC, and KA samples. The both TEs were negative in this regard.

Conclusion: This study showed that the incidence rate of p53- and Ki67-positive cells is very high in skin malignant epithelial tumors. The expression rate of these two variables is comparable with reports in the literature. Further studies with large sample size are recommended to be carried out for KA and TE samples.

Keywords: Epithelial tumors; Ki67; p53; tumor marker.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: Nil.

Figures

Figure 1
Figure 1
Squamous cell carcinoma of skin, Immunostained for p53, nuclear positivity (arrow), 10×40
Figure 2
Figure 2
Squamous cell carcinoma of skin, Immunostained for Ki67, nuclear positivity (arrows), 10×40
Diagram 1
Diagram 1
Abundance distribution of p53 protein in basal cell carcinomas
Diagram 2
Diagram 2
Abundance distribution of Ki67 antigen in basal cell carcinomas
Diagram 3
Diagram 3
Abundance distribution of p53 protein in squamous cell carcinomas
Diagram 4
Diagram 4
Abundance distribution of Ki67 antigen in squamous cell carcinomas
See this image and copyright information in PMC

References

    1. Dyer RK, Weinstock MA, Cohen TS, Rizzo AE, Bingham SF. Predictors of basal cell carcinoma in high-risk patients in the VATTC (VA topical tretinoin chemoprevention) Trial. J Invest Dermatol. 2012;132:2544–51. - PubMed
    1. Amirnia M, Babaie-Ghazani A, Fakhrjou A, Khodaeiani E, Alikhah H, Naghavi-Behzad M, et al. Immunohistochemical study of cyclooxygenase-2 in skin tumors. J Dermatolog Treat. 2012. Jun 5, http://www.ncbi.nlm.nih.gov/pubmed/22667343. [Epub ahead of print] - PubMed
    1. Vidal D, Matías-Guiu X, Alomar A. Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis. Br J Dermatol. 2004;151:656–62. - PubMed
    1. Ansarin H, Daliri M, Soltani-Arabshahi R. Expression of p53 in aggressive and non-aggressive histologic variants of basal cell carcinoma. Eur J Dermatol. 2006;16:543–7. - PubMed
    1. Khodaeiani E, Amirnia M, Nazhad SB, Esmaeili H, Karimi ER, Alikhah H. Clinicopathologic study of basal cell carcinoma. Res J Biol Sci. 2010;5:293–6.

LinkOut - more resources